Downs Louise O, McNaughton Anna L, de Cesare Mariateresa, Ansari M Azim, Martin Jacqueline, Woodrow Charles, Bowden Rory, Collier Jane, Barnes Eleanor, Matthews Philippa C
Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.
Nuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Rd, Oxford, OX1 3SY, UK.
Wellcome Open Res. 2021 Jan 25;5:240. doi: 10.12688/wellcomeopenres.16157.2. eCollection 2020.
Deep sequencing of the full-length hepatitis B virus (HBV) genome provides the opportunity to determine the extent to which viral diversity, genotype, polymorphisms, insertions and deletions may influence presentation and outcomes of disease. Increasing experience with analysis of HBV genomic data opens up the potential for using these data to inform insights into pathophysiology of infection and to underpin decision making in clinical practice. We here set out to undertake whole genome HBV sequencing from an adult who presented acutely unwell with a new diagnosis of HBV infection, and tested positive for both HBV anti-core IgM and IgG, possibly representing either acute hepatitis B infection (AHB) or chronic hepatitis B with an acute reactivation (CHB-AR). The distinction between these two scenarios may be important in predicting prognosis and underpinning treatment decisions, but can be challenging based on routine laboratory tests. Through application of deep whole-genome sequencing we typed the isolate as genotype-D1, and identified several minority variants including G1764A and G1986A substitutions in the pre-core promoter and pre-core regions, which support CHB-AR rather than AHB. In the longer term, enhanced deep sequencing data for HBV may provide improved evidence to distinguish between acute and chronic infection, to predict outcomes and to stratify treatment.
对全长乙型肝炎病毒(HBV)基因组进行深度测序,为确定病毒多样性、基因型、多态性、插入和缺失可能影响疾病表现及转归的程度提供了契机。随着对HBV基因组数据分析经验的不断增加,利用这些数据深入了解感染的病理生理学并为临床实践中的决策提供依据成为可能。我们在此对一名因新诊断为HBV感染而急性不适的成年人进行了全基因组HBV测序,该患者的HBV抗核心IgM和IgG检测均呈阳性,可能代表急性乙型肝炎感染(AHB)或慢性乙型肝炎急性再激活(CHB-AR)。这两种情况的区分对于预测预后和支持治疗决策可能很重要,但基于常规实验室检查可能具有挑战性。通过应用深度全基因组测序,我们将分离株分型为D1基因型,并鉴定出几个少数变异体,包括前核心启动子和前核心区域中的G1764A和G1986A替换,这些支持CHB-AR而非AHB。从长远来看,增强的HBV深度测序数据可能为区分急性和慢性感染、预测转归及分层治疗提供更好的证据。